Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genenta Science S.p.A. (NASDAQ: GNTA) SEC filings page on Stock Titan brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a foreign private issuer and clinical-stage immuno-oncology company, Genenta reports key information about its Temferon™ development programs, financing activities, and governance through Form 6-K and related filings.
In these filings, investors can find unaudited consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which outline Genenta’s cash resources, operating expenses, and funding runway in relation to its solid tumor clinical programs. Other 6-Ks describe registered direct offerings of American Depositary Shares under a shelf registration statement on Form F-3, including purchase agreements, placement agency agreements, and use-of-proceeds language.
Genenta also uses SEC filings to document a Mandatory Convertible Bond financing with ENEA Tech and Biomedical, amendments to its by-laws, changes in the size and composition of its Board of Directors, and executive leadership transitions such as the appointment or resignation of a Chief Medical Officer. Shareholder meeting notices and outcomes, including approvals of statutory financial statements and director appointments, are similarly detailed in these reports.
Through Stock Titan, users can access Genenta’s 6-Ks, registration statements, prospectus supplements, and related exhibits as they are made available on EDGAR, along with AI-powered summaries that explain the practical meaning of each document. This includes highlighting where Genenta discusses its Temferon clinical trials in glioblastoma multiforme and metastatic renal cell carcinoma, capital structure changes, and material agreements with manufacturing partners. For those monitoring insider holdings, the SEC database also provides ownership and transaction reports that complement the company’s own ownership updates.
Use this page to quickly review GNTA’s latest SEC filings, compare new disclosures with prior reports, and understand how regulatory documents reflect the evolution of Genenta’s immuno-oncology platform and corporate strategy.
Genenta Science S.p.A. (GNTA) reported outcomes from its Ordinary and Extraordinary Shareholders’ Meeting. Directors Armon R. Sharei, Francesco Galimi, and CEO Pierluigi Paracchi will continue on the Board, and two new directors were appointed: Miguel Maria Mutti, a senior pharma and investment banking executive, and Giacomoantonio Paracchi, a business lawyer and brother of the CEO.
Shareholders approved an amendment to Article 4 of the by-laws to extend the corporate purpose to sectors covered by Italy’s Golden Power legislation. Effectiveness is expressly conditioned on no shareholder exercising the statutory withdrawal right; a single valid withdrawal makes the amendment ineffective and does not trigger share liquidation. The withdrawal right must be exercised by registered letter within 15 days of registration of the resolution, i.e., by about November 15, 2025.
The amended by-laws were filed as Exhibit 3.1. The filing notes a recent capital increase with 4,285,715 new shares and that updated by-laws reflecting share capital will be filed within 30 days from execution.
Genenta Science S.p.A. (GNTA) is conducting a registered direct primary offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of $15,000,002.50. After placement agent fees of $900,000.15 and estimated expenses, the company expects net proceeds of approximately $13.8 million, which it intends to use for working capital and general corporate purposes. The ADSs are listed on Nasdaq under “GNTA,” and delivery is expected on or about October 28, 2025.
Maxim Group LLC and Rodman & Renshaw LLC are acting as placement agents on a reasonable best efforts basis. The company reports as adjusted net tangible book value of $1.16 per ADS, implying immediate dilution of $2.34 per ADS to new investors. Ordinary Shares outstanding are expected to be 23,432,183 after the offering. The last reported GNTA price on October 24, 2025 was $6.20 per ADS.
Genenta Science S.p.A. (GNTA) entered into a registered direct offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of approximately $15.0 million, expected to close on or about October 28, 2025 subject to customary conditions. Each ADS represents one ordinary share.
The company plans to use net proceeds for working capital and general corporate purposes. The sale is being made under a prospectus supplement to Genenta’s effective Form F-3 shelf.
Maxim Group LLC (lead) and Rodman & Renshaw LLC (co-placement agent) are acting as placement agents; Genenta will pay a 6.0% cash fee on aggregate gross proceeds and up to $75,000 for expenses. For 90 days after closing, the company, and separately its officers and directors under lock-up agreements, agree to restrictions on issuing or selling company securities, with limited exceptions. The company also agreed not to conduct variable rate transactions for six months.
Genenta Science S.p.A. (GNTA) reported outcomes from its April 29, 2025 Annual Ordinary Shareholders’ Meeting. Shareholders approved the statutory financial statements for the year ended December 31, 2024, audited by Revicom.
They appointed three directors effective April 29, 2025, adding Dr. Francesco Galimi as a new member. Armon R. Sharei, Ph.D. continued on the Board, and Pierluigi Paracchi continued as Chairman. The term of office for each newly appointed director is one year.
The aggregate annual directors’ compensation was set at €105,000. On April 30, 2025, the directors appointed Mr. Paracchi as Chief Executive Officer and allocated annual compensation of €45,000 for the CEO and €30,000 for each of Dr. Galimi and Dr. Sharei.
FAQ
What is the current stock price of Genenta Science Spa (GNTA)?
What is the market cap of Genenta Science Spa (GNTA)?
